IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

First U.S. site for IceCure’s breast cancer study opens, but impact remains unproven.

What the company is saying

IceCure Medical Ltd. is announcing the West Cancer Center & Research Institute as the first U.S. clinical site for its post-marketing ChoICE Study of the ProSense® cryoablation system in low-risk breast cancer. The company frames this as a milestone for U.S. clinical adoption, emphasizing the study’s scale—up to 400 patients across 30 sites—and the FDA’s clearance of ProSense® for a narrowly defined patient group. The announcement highlights the dual role of participating sites as both study and commercial centers, suggesting immediate clinical integration. Language throughout stresses the potential for broader access and adoption, but omits any financial data, commercial agreements, or timelines for enrollment completion. The tone is optimistic and forward-looking, with repeated references to leadership and innovation, but provides no evidence of actual market traction or realized patient benefit. Dr. Richard Gilmore and CEO Eyal Shamir are named, but their involvement is limited to institutional roles rather than personal investment or endorsement.

What the data suggests

The only concrete numbers disclosed are the planned enrollment of up to 400 patients, the involvement of 30 U.S. sites, and the FDA clearance for patients aged 70 and older with tumors ≤1.5 cm. No figures are provided for actual patient enrollment, commercial sales, or financial performance. The FDA clearance is a realised fact, but applies only to a small subset of breast cancer patients. There is no data on how many sites are currently active, how many patients have been treated, or any early outcomes. The claim that ProSense® is marketed and sold worldwide is unsupported by sales or clearance data outside the U.S. The study’s design allows sites to treat patients outside the trial, but there is no evidence this is occurring. Overall, the data supports only the initiation of a clinical study and regulatory clearance for a limited indication, not broader adoption or financial progress.

Analysis

The announcement is framed in a positive tone, highlighting the initiation of the first U.S. clinical site for the ChoICE Study and the potential for broader adoption of ProSense®. However, most key claims are forward-looking, such as the projected enrollment of 400 patients, the anticipated impact on clinical adoption, and the expansion of commercial access. Only a minority of claims are realised facts, such as FDA clearance for a specific indication and the historical service of the West Cancer Center. There is no disclosure of financial metrics, profitability, or immediate commercial impact, and no capital outlay is described. The language inflates the signal by implying broad commercial momentum and leadership without supporting data. The actual evidence supports only the initiation of a clinical study and regulatory clearance for a narrow patient group, not widespread adoption or financial success.

Risk flags

• ●The announcement is almost entirely forward-looking, with most claims about adoption, access, and commercial integration lacking supporting data. This matters because the gap between projected and realised impact is wide, and investors have no way to gauge near-term revenue or adoption.
• ●No financial figures, commercial agreements, or sales data are disclosed. The absence of these metrics prevents any assessment of financial health, cash runway, or the commercial value of the ChoICE Study.
• ●The FDA clearance is limited to patients aged 70+ with tumors ≤1.5 cm, a small subset of the breast cancer population. This restricts the addressable market and raises questions about the broader relevance of the study and system.
• ●The study’s success depends on enrolling 400 patients across 30 sites, but no details are given about site activation, recruitment pace, or contingency plans if enrollment lags. This introduces significant execution risk, as under-enrollment would undermine the study’s value.

Bottom line

This announcement signals the start of IceCure’s U.S. post-marketing study for ProSense®, but offers no evidence of commercial traction or near-term revenue. The company’s narrative is built on future potential—broader adoption, increased access, and real-world data—but these outcomes depend on successful patient enrollment and positive study results, neither of which are guaranteed or even underway at scale. The FDA clearance is real, but applies to a narrow patient group, limiting immediate market opportunity. No financial data or commercial agreements are disclosed, leaving investors unable to assess the company’s financial direction or the study’s economic impact. Unless future updates provide enrollment progress, sales figures, or reimbursement milestones, the investment case remains speculative. The key takeaway is that while the clinical study launch is a necessary step, its commercial and financial significance is unproven and distant.

Announcement summary

(NASDAQ:ICCM) IceCure Medical Ltd. announced that the West Cancer Center & Research Institute in Germantown, Tennessee will serve as the first U.S. clinical site for the Company's post-marketing study "ChoICE" for ProSense® cryoablation in the treatment of low-risk breast cancer, following FDA marketing authorization in October 2025. The ChoICE Study will enroll up to 400 patients across 30 U.S. sites, gathering real-world data to support further clinical adoption and broader access for eligible patients. ProSense® is cleared by the U.S. Food and Drug Administration for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible for surgery. Under the approved study design, 30 participating sites will serve both as ChoICE Study sites and as active commercial sites, enabling them to enroll and treat a total of 400 patients while also offering ProSense® cryoablation to appropriate patients who are not participating in the ChoICE Study. IceCure Medical develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors, with primary focus areas being breast, kidney, bone, and lung cancer. The company projects that the ChoICE Study and the resulting data will support clinical and commercial adoption of ProSense® and broader patient access. The West Cancer Center & Research Institute has served the Mid-South for 47 years and continues as the leader in adult cancer care.

Disagree with this article?